您好，欢迎来到半岛电竞官方网址 ！ [ 登录] [ 免费注册]
半岛电竞官方网址
发布求购
位置： 首页> 半岛bd体育手机客户端 库> O-Acetyl Salicylhydroxamic Acid
立即咨询
咨询类型：
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
O-Acetyl Salicylhydroxamic Acid
本半岛bd体育手机客户端 不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
O-Acetyl Salicylhydroxamic Acid图片
CAS NO: 199854-00-7
包装与价格：
包装 价格(元)
5mg 电议
10mg 电议
50mg 电议

半岛bd体育手机客户端 介绍

化学性质

Physical Appearance A crystalline solid
Storage Store at -20°C
M.Wt 195.2
Cas No. 199854-00-7
Formula C9H9NO4
Synonyms AcSHA,O-ASHA
Solubility ≤25mg/ml in ethanol;50mg/ml in DMSO;30mg/ml in dimethyl formamide
Chemical Name N-(acetyloxy)-2-hydroxy benzamide
Canonical SMILES CC(=O)ONC(=O)c1ccccc1O
运输条件 蓝冰运输或根据您的需求运输。
一般建议 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次半岛bd体育手机客户端 溶解度各有差异，仅做参考。若实验所需浓度过大至半岛bd体育手机客户端 溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

O-Acetyl Salicylhydroxamic Acid (O-ASHA) is an irreversible, non-selective inhibitor of COX-1 and COX-2 [1].

Cyclooxygenase (COX) is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Cyclooxygenase enzymes have been involved in diverse physiological situations and disease processes ranging from inflammation to cancer. Until now, two cyclooxygenase isoforms have been identified, COX-1 and COX-2. The COX-1 enzyme is produced constitutively (i.e., gastric mucosa) and COX-2 is inducible (i.e., sites of inflammation) [2].

O-Acetyl Salicylhydroxamic Acid (O-ASHA) inhibited the activity of ovine COX-1 in a time-dependent and irreversible manner with a 50% B/B0 value of approximately 4.5 mM [1]. O-Acetyl Salicylhydroxamic Acid was a novel acetylating agent. O-Acetyl Salicylhydroxamic Acid inhibited PGE2 synthesis in vivo and blocked the cyclooxygenase activity of PGHS in vitro. O-Acetyl Salicylhydroxamic Acid elicited its effects via acetylation of Ser-529 in the cyclooxygenase active site [1].

References:
[1] Loll P J, Sharkey C T, O'Connor S J, et al. O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions[J]. Molecular pharmacology, 2001, 60(6): 1407-1413.
[2] Dubois R N, Abramson S B, Crofford L, et al. Cyclooxygenase in biology and disease[J]. The FASEB journal, 1998, 12(12): 1063-1073.

Baidu
map